144 related articles for article (PubMed ID: 31369545)
21. An economic evaluation of the current measles vaccination program: A case study in Zhejiang Province, east China.
Zeng Y; Luo M; Chen J; He H; Deng X; Xie S; Fang Y
Vaccine; 2019 May; 37(23):3071-3077. PubMed ID: 31040084
[TBL] [Abstract][Full Text] [Related]
22. The cost saving opportunity of introducing a card review into measles-containing vaccination campaigns.
Hagedorn BL; Dabbagh A; McCarthy KA
Vaccine; 2019 Sep; 37(41):6093-6101. PubMed ID: 31471145
[TBL] [Abstract][Full Text] [Related]
23. Cost effectiveness of prevaccination screening of health care workers for immunity to measles, rubella and mumps.
Ferson MJ; Robertson PW; Whybin LR
Med J Aust; 1994 Apr; 160(8):478-82. PubMed ID: 8170422
[TBL] [Abstract][Full Text] [Related]
24. Measles-mumps-rubella immunization of susceptible hospital employees during a community measles outbreak: cost-effectiveness and protective efficacy.
Stover BH; Adams G; Kuebler CA; Cost KM; Rabalais GP
Infect Control Hosp Epidemiol; 1994 Jan; 15(1):18-21. PubMed ID: 8133004
[TBL] [Abstract][Full Text] [Related]
25. [Review of the 2016 Swiss immunization schedule and technology update for improving vaccine management].
Diana A
Rev Med Suisse; 2016 May; 12(518):949-53. PubMed ID: 27352591
[TBL] [Abstract][Full Text] [Related]
26. The economic disease burden of measles in Japan and a benefit cost analysis of vaccination, a retrospective study.
Takahashi K; Ohkusa Y; Kim JY
BMC Health Serv Res; 2011 Oct; 11():254. PubMed ID: 21978107
[TBL] [Abstract][Full Text] [Related]
27. Optimization of frequency and targeting of measles supplemental immunization activities in Nigeria: A cost-effectiveness analysis.
Zimmermann M; Frey K; Hagedorn B; Oteri AJ; Yahya A; Hamisu M; Mogekwu F; Shuaib F; McCarthy KA; Chabot-Couture G
Vaccine; 2019 Sep; 37(41):6039-6047. PubMed ID: 31471147
[TBL] [Abstract][Full Text] [Related]
28. Global eradication of measles: an epidemiologic and economic evaluation.
Levin A; Burgess C; Garrison LP; Bauch C; Babigumira J; Simons E; Dabbagh A
J Infect Dis; 2011 Jul; 204 Suppl 1():S98-106. PubMed ID: 21666220
[TBL] [Abstract][Full Text] [Related]
29. Pre-vaccination IgG screening for mumps is the most cost-effectiveness immunization strategy among Health Care Workers.
Coppeta L; Balbi O; Baldi S; Pietroiusti A; Magrini A
Hum Vaccin Immunother; 2019; 15(5):1135-1138. PubMed ID: 30779686
[TBL] [Abstract][Full Text] [Related]
30. Economic analyses of rubella and rubella vaccines: a global review.
Hinman AR; Irons B; Lewis M; Kandola K
Bull World Health Organ; 2002; 80(4):264-70. PubMed ID: 12075361
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of supplementary immunization for measles in India.
Dabral M
Indian Pediatr; 2009 Nov; 46(11):957-62. PubMed ID: 19578225
[TBL] [Abstract][Full Text] [Related]
32. Comparing measles with previous eradication programs: enabling and constraining factors.
Keegan R; Dabbagh A; Strebel PM; Cochi SL
J Infect Dis; 2011 Jul; 204 Suppl 1():S54-61. PubMed ID: 21666211
[TBL] [Abstract][Full Text] [Related]
33. Measles and human movement in Europe.
Massad E
J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30312454
[No Abstract] [Full Text] [Related]
34. Measles: not just another viral exanthem.
Duke T; Mgone CS
Lancet; 2003 Mar; 361(9359):763-73. PubMed ID: 12620751
[TBL] [Abstract][Full Text] [Related]
35. [Are measles and mumps vaccinations worth while in Switzerland?].
Just M
Schweiz Med Wochenschr; 1978 Nov; 108(45):1763-8. PubMed ID: 100878
[TBL] [Abstract][Full Text] [Related]
36. Measles: taking steps forward to prevent going backwards.
Gupta K; Chen M; Rocker J
Curr Opin Pediatr; 2020 Jun; 32(3):436-445. PubMed ID: 32374581
[TBL] [Abstract][Full Text] [Related]
37. The economics of screening for measles.
Sellick JA
Pharmacoeconomics; 1992 Dec; 2(6):440-3. PubMed ID: 10147004
[No Abstract] [Full Text] [Related]
38. Increase of vaccination coverage by mass media and individual approach: intensified measles, mumps, and rubella prevention program in Finland.
Paunio M; Virtanen M; Peltola H; Cantell K; Paunio P; Valle M; Karanko V; Heinonen OP
Am J Epidemiol; 1991 Jun; 133(11):1152-60. PubMed ID: 2035518
[TBL] [Abstract][Full Text] [Related]
39. Economic analysis of the 1996-1997 mass measles immunization campaigns in South Africa.
Uzicanin A; Zhou F; Eggers R; Webb E; Strebel P
Vaccine; 2004 Sep; 22(25-26):3419-26. PubMed ID: 15308367
[TBL] [Abstract][Full Text] [Related]
40. Economic evaluation of vaccination programme of mumps vaccine to the birth cohort in Japan.
Hoshi SL; Kondo M; Okubo I
Vaccine; 2014 Jul; 32(33):4189-97. PubMed ID: 24923640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
